Chemotherapy–induced anemia (CIA)
In anemic patients with cancer with non–myeloid malignancies receiving myelosuppressive chemotherapy
divider
Expected rise in Hb starting at Week 41
Expected rise in Hb starting at Week 4
Study design
A randomized, double–blind, placebo–controlled, 16–week clinical study in 344 patients with anemia receiving concomitant chemotherapy for cancer. Patients received PROCRIT® 40,000 U (n=174) or placebo (n=170) SC weekly for 16 weeks.1,2

  • Patients receiving PROCRIT® had a significant increase in Hb compared with patients receiving placebo starting at Week 4 and through the rest of the study (Week 16) (P<0.001)1
  • Over the course of the study, 73% of patients receiving PROCRIT® achieved a ≥2 g/dL increase in Hb compared with 32% of patients receiving placebo (P<0.0001)1
  • RBC transfusions and/or PROCRIT® dose adjustments were permitted1
divider
Reduces the need for transfusions1,2
Reduces the need for transfusions
Study design
A randomized, double–blind, placebo-controlled, 16–week clinical study in 344 patients with anemia receiving concomitant chemotherapy for cancer. Patients received PROCRIT® 40,000 U (n=174) or placebo (n=170) SC weekly for 16 weeks.1,2
  • 28% of placebo–treated patients received transfusions, compared with 14% of PROCRIT®–treated patients (P=0.001)1,2
Maintaining Hb rise with erythropoiesis–stimulating agents (ESAs) is essential to avoiding transfusions

divider
Selected safety profile
Adverse reactions occurring in ≥5% of patients2*

Adverse reaction PROCRIT®–treated patients (n=168) Placebo–treated patients (n=165)
Nausea 35% 30%
Vomiting 20% 16%
Myalgia 10% 5%
Arthralgia 10% 6%
Stomatitis 10% 8%
Cough 9% 7%
Weight decline 9% 5%
Leukopenia 8% 7%
Bone pain 7% 4%
Rash 7% 5%
Hyperglycemia 6% 4%
Insomnia 6% 2%
Headache 5% 4%
Depression 5% 4%
Dysphagia 5% 2%
Hypokalemia 5% 3%
Thrombosis 5% 3%
  • From a double–blind, placebo–controlled, 16–week study with 333 cancer patients with anemia due to chemotherapy2
*Adverse reactions with a reported incidence of ≥5% in PROCRIT®–treated patients that occurred at a higher frequency than in placebo–treated patients.2
divider

References
  1. Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III, randomized, double–blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol. 2005;23:2606-2617.
  2. PROCRIT (epoetin alfa) Prescribing Information. Janssen Products, LP.
 
Indications and Important Safety Information
EXPAND    Expand ISI
INDICATIONS
Expand ISI
IMPORTANT SAFETY INFORMATION
Expand ISI